Product nameAnti-uPA antibody [EP6274(2)]
See all uPA primary antibodies
DescriptionRabbit monoclonal [EP6274(2)] to uPA
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Human
Predicted to work with: Chimpanzee
A synthetic peptide corresponding to residues in human PLAU, P00749.
- PC3 cell lysate. PC3 cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab169754 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 48 kDa.|
|ICC/IF||1/50 - 1/100.|
RelevanceUrokinase type plasminogen activator (uPA) is secreted from cells as a precursor which is activated to the two chain form consisting of an A and B chain. The active high MW form is further processed by removal of an amino terminal fragment to an active low MW form (35 kDa). uPA is a serine protease that activates plasminogen toplasmin. High levels of uPA and plasminogen activator inhibitor type 1 (PAI 1) in breast cancer tissue extracts have been associated with rapid disease progression. The malignant phenotype of prostatic tumor cells correlates with the expression of both uPA and its cell membrane receptor (uPAR).
- ATF antibody
- BDPLT5 antibody
- EC 188.8.131.52 antibody
This product has been referenced in:
- Iesato A et al. PATZ1 knockdown enhances malignant phenotype in thyroid epithelial follicular cells and thyroid cancer cells. Oncotarget 8:82754-82772 (2017). Read more (PubMed: 29137300) »
- Hao XD et al. De novo mutations of TUBA3D are associated with keratoconus. Sci Rep 7:13570 (2017). Read more (PubMed: 29051577) »